gefitinib + bicalutamide

Gefitinib + bicalutamide is an investigational combination therapy comprising two small-molecule drugs: gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and bicalutamide, a nonsteroidal antiandrogen and androgen receptor antagonist. Gefitinib inhibits EGFR-mediated signaling, thereby blocking pathways involved in cell proliferation and survival. Bicalutamide binds androgen receptors, preventing androgen-driven tumor growth primarily in prostate tissue. The combination is being studied for its additive or synergistic antitumor effects, particularly in prostate cancer, by concurrently inhibiting AR- and EGFR-mediated growth pathways. Dual blockade is of interest for delaying the onset of androgen independence in prostate cancer, where monotherapy with either agent may be insufficient[1][3].